A Travers Smith team led by head of private equity, Paul Dolman and private equity senior associate, Will Yates has advised the shareholders (including majority shareholder Lyceum Capital) of international clinical trial research firm Synexus on its £83 million secondary buy-out backed by private equity investor LDC.
Lyceum took Synexus private from AIM in 2007 in a £18 million deal. Synexus' clients include many of the world's largest pharmaceutical companies and contract research organisations, for which it recruits and treats patients in clinical trials in support of drug research.
With Lyceum's backing, the firm has expanded in the UK and internationally, growing from 13 sites at acquisition to 25 sites in 8 countries today.
The Travers Smith team included corporate associate Stacey Beggs, tax partner Russell Warren, tax senior associate Jessica Kemp and tax associate Tom Rickford. LDC was advised by DLA.